addiction

BP 897 is a potent and selective agonist of dopamine D3 receptor and it is a weak dopamine D2 receptor antagonist, with Kis of 0.92 nM and 61 nM for D3 and D2 receptors. Which shows low affinities at D1 and D4 receptors (Kis, 3 and 0.3 μM, respectively).

AZD-8529 mesylate is a highly selective, and orally bioavailable positive allosteric modulator of mGluR2 (EC50: 285 nM). It shows no positive allosteric modulator responses at 20-25 M on the mGluR1, 3, 4, 5, 6, 7, and 8 subtypes.

Fenobam shows inverse agonist activity which blocks the mGlu5 receptor basal activity(IC50: 84 nM). Fenobam has anxiolytic activity. Fenobam is a selective and non-competitive mGluR5 antagonist acting at an allosteric modulatory site (Kd values are 54 and 31 nM for rat and human recombinant mGlu5 receptors, respectively).

OS-3-106 is a novel arylamide phenylpiperazines, as partial agonists at the D3R in the adenylyl cyclase inhibition assay.

Varenicline dihydrochloride is a Selective α4β2 nicotinic acetylcholine receptor partial agonist.

neuropeptide S receptor (NPSR) antagonist

NGB 2904 is a potent and selective antagonist of dopamine D3 receptor (Ki values are 1.4, 217, 223, 642, > 5000, > 10000 and > 10000 nM for D3, D2, 5-HT2, α1, D4, D1 and D5 receptors respectively). NGB2904 potently antagonizes mitogenesis stimulated by quinpirole (IC50 = 6.8 nM).

BP 897 (2-Naphthalenecarboxamide, N-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]-) is a potent and selective dopamine D3 receptor agonist, and a weak dopamine D2 receptor antagonist, with Kis of 0.92 nM and 61 nM for D3 and D2 receptors, and shows low affinities at D1 and D4 receptors (Kis, 3 and 0.3 μM, respectively).

Oxeladin citrate is a highly potent and effective cough suppressant, which can treat all types of cough of various etiologies. It is not related to opium or its derivatives, so treatment with oxeladin is no risk of addiction. And it has none of the side effects (such as hypnosis, respiratory depression, tolerance, constipation and analgesia) which are present when common antitussives. It can used at every age, as well as in patients with heart disease, since it is high level of safety and a great selectivity to act on the bulbar centre of cough.

Naltrexone hydrochloride (Naltrexone HCl) is a synthetic opioid antagonist used in the prevention of relapse of opiate addiction and alcoholism.

7-Keto DHEA binds to the gamma-aminobutyric acid (GABA) receptor. Studies 7-Keto DHEA reduces ethanol intake in rat models, indicating a modulatory effect on alcohol consumption behavior. 7-Keto DHEA therefore exhibits potential as a investigational compound of alcohol dependence disorders, contributing to the broader field of addiction research.

CB1R Allosteric modulator 3 is a potent CB1R modulator that inhibits cAMP and β-Arrestin and can be used for the study of obesity and nicotine addiction.

GSK1521498 free base is an effective and selective μ-opioid receptor antagonist with potential applications in obesity, alcoholism, and drug addiction.

Pozanicline reverses nicotine withdrawal-induced cognitive deficits, may be an effective component of novel therapeutic strategies for nicotine addiction. Pozanicline selectively activate neuronal nicotinic acetylcholine receptor (nAChR) subtypes, is a no

Eglumetad (also known as LY354740) is an investigational compound developed by Eli Lilly and Company, currently under research for the treatment of anxiety disorders and substance addiction. This compound originates from glutamate, demonstrating a novel mechanism of action.

VU0469650 hydrochloride is a brain-penetrant negative allosteric modulator of the metabotropic glutamate receptor 1 (mGluR1). It inhibits glutamate-induced calcium flux in cells expressing human mGluR1 with an IC50 of 99 nM. VU0469650 hydrochloride holds potential for research into central nervous system disorders such as anxiety, addiction, and epilepsy.

Anticanceragent 192 (compound XXI) is a steroid-based histamine H3 receptor antagonist with no affinity for muscarinic and hERG receptors. It shows considerable stability in human and rat liver microsomes. Additionally, in addiction tests conducted on rats, Anticanceragent 192 enhances cognitive levels and reduces addiction severity.

GABAB receptor antagonist 5 (Compound 23) is a competitive antagonist of the GABAB receptor. It holds potential for research into neuropsychiatric disorders, including epilepsy, depression, and addiction.

Dopamine D3 receptor ligand-6 (Compound 196476) is a selective antagonist of the dopamine D3 receptor (D3). It holds potential for research in substance use disorders, including opioid and psychostimulant addiction.

F4-Trp (4,5,6,7-Tetrafluoro-L-tryptophan) is a ligand specifically targeting the α3β4 subtype of nicotinic acetylcholine receptors (α3β4nAChR). This compound holds potential for research in neurotransmission, addiction, and related conditions, including neurological disorders.

5-HT2C agonist-9 (Compound 33) is a 5-HT2C receptor agonist with an EC50 of 1.4 nM for h5-HT2C. It is utilized in research related to conditions such as depression, drug addiction, alcohol dependence, PTSD, and neuropathic pain.

5-HT2A agonist 4 (Compound 70) is a 5-HT2A agonist with an EC50 value of 0.30 nM for h5-HT2A. It can be utilized in research related to depression, substance addiction, alcoholism, post-traumatic stress disorder (PTSD), and neuropathic pain.

5-HT2A agonist 5 (Compound 88) is a 5-HT2A agonist with an EC50 of 0.01 nM for h5-HT2A. It can be utilized in research concerning depression, drug addiction, alcoholism, post-traumatic stress disorder (PTSD), and neuropathic pain.

5-HT2AR-IN-1 (Compound Ie) is an orally active inhibitor of the serotonin 2A receptor (5-HT2AR) with antidepressant effects. It reduces the expression of 5-HT2AR and levels of SERT protein. This compound holds potential for research in central nervous system (CNS) conditions, including depression and addiction-related disorders.